Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?

05 Aug 2016

• By Michael Cipriano

Related Content

AbbVie Seeks Strict Interchangeability Standards For Biosimilars

31 Dec 2015

Biosimilar Labeling Variation From Reference Product OK, FDA Says

04 Apr 2016

Biosimilar Labeling In US Needs Greater Transparency, BIO And PhRMA Say

08 Jan 2016

Biosimilar Labeling: FDA Says Leave Comparability Data Out

31 Mar 2016

Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting

05 Aug 2016

Related Companies

Sanofi

Takeda Pharmaceutical Co. Ltd.

Genentech, Inc.

Pfizer Inc.

AbbVie Inc.

Amgen, Inc.

Novartis AG

Merck & Co., Inc.

Boehringer Ingelheim GmbH

Additional Topics

United States Biosimilars Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.